Newsletter
Browse all issues →Liquid Pulse — a monthly read on what’s new in the field
Latest issue: Liquid Pulse — October 2026
Recent developments
Reading EGFR in Plasma: What ctDNA Testing Can and Can't Tell You in Lung CancerWhat plasma / ctDNA testing for EGFR mutation can and cannot determine, and where the evidence stands. Evidence-based, with primary citations.The CTC Clinical-Utility Limit: What SWOG S0500 Taught Us About Circulating Tumor Cells in Metastatic Breast CancerThe CTC Clinical-Utility Limit: SWOG S0500: what the blood-based assay can and cannot determine, and where the evidence stands. Evidence-based, with primarReading the Blood Instead of the Bone: ctDNA–Tissue Concordance in Metastatic Prostate CancerProstate ctDNA-Tissue Concordance and Plasma Genotyping: what the blood-based assay can and cannot determine, and where the evidence stands. Evidence-basedPost-Operative ctDNA (MRD) in Colorectal Cancer: What the DYNAMIC Trial Actually ShowedPost-Operative ctDNA (MRD) in Colorectal Cancer: the DYNAMIC Trial: what the blood-based assay can and cannot determine, and where the evidence stands. EviWhen the Tumor Isn't on the Slide: Analytic Validation of Plasma NGS PlatformsPlasma-vs-Tissue Platform Analytic Validation: what the blood-based assay can and cannot determine, and where the evidence stands. Evidence-based, with priPlasma PIK3CA Mutation Testing and the Selection of PI3K–AKT Pathway Inhibitors in HR+ Breast CancerPlasma PIK3CA Mutation: PI3K-AKT Inhibitor Selection: what the blood-based assay can and cannot determine, and where the evidence stands. Evidence-based, wOvarian ctDNA-MRD and Recurrence Detection: An Emerging but Investigational ToolOvarian ctDNA-MRD and Recurrence Detection: what the blood-based assay can and cannot determine, and where the evidence stands. Evidence-based, with primarWhat a Blood Test for Colorectal Cancer Can and Cannot Tell You: The Methylated-SEPT9 AssayMethylated-SEPT9 Plasma Assay for Colorectal Cancer Detection: what the blood-based assay can and cannot determine, and where the evidence stands. EvidenceLung Plasma Genotyping: Comprehensive cfDNA Versus Tissue in Advanced NSCLCLung Plasma Genotyping: Comprehensive cfDNA vs Tissue: what the blood-based assay can and cannot determine, and where the evidence stands. Evidence-based, Plasma EGFR T790M Monitoring in NSCLC: What a Negative Result Can — and Cannot — Tell YouLung Plasma EGFR T790M Monitoring: what the blood-based assay can and cannot determine, and where the evidence stands. Evidence-based, with primary citatioLung Per-Driver Plasma Concordance: Reading a Blood Genotype Driver by Driver in NSCLCLung Per-Driver Plasma Concordance: what the blood-based assay can and cannot determine, and where the evidence stands. Evidence-based, with primary citatictDNA-MRD in Resected Colorectal Cancer: Surveillance and Adjuvant GuidancectDNA-MRD in Resected Colorectal Cancer: Surveillance and Adjuvant Guidance: what the blood-based assay can and cannot determine, and where the evidence stBreast ctDNA-MRD: Personalized Relapse Prediction in Early-Stage DiseaseBreast ctDNA-MRD: Personalized Relapse Prediction: what the blood-based assay can and cannot determine, and where the evidence stands. Evidence-based, withAR-V7 (Circulating Tumor Cell mRNA/Protein): mCRPC Resistance BiomarkerAR-V7 (Circulating Tumor Cell mRNA/Protein): mCRPC Resistance Biomarker: what the blood-based assay can and cannot determine, and where the evidence standsAcquired ESR1 Mutations in Plasma: Reading Endocrine Resistance in Real TimeWhat plasma / ctDNA testing for ESR1 mutation (acquired) can and cannot determine, and where the evidence stands.Detecting HER2 Mutations in ctDNA: What a Blood Test Can (and Can't) CatchWhat plasma / ctDNA testing for ERBB2 / HER2 mutation can and cannot determine, and where the evidence stands.HRR Deficiency from a Blood Draw: What Plasma ctDNA RevealsWhat plasma / ctDNA testing for Germline / somatic HRR alterations (BRCA2, BRCA1, ATM, others) can and cannot determine, and where the evidence stands. EviBRAF V600E in Plasma: What a Drop of ctDNA Can (and Can't) Tell YouWhat plasma / ctDNA testing for BRAF V600E mutation can and cannot determine, and where the evidence stands.Can Plasma Track CD20? The Limits of ctDNA After Anti-CD20 TherapyWhat plasma / ctDNA testing for CD20 can and cannot determine, and where the evidence stands.Tracking ALK Fusions in Plasma: What Liquid Biopsy Adds — and MissesWhat plasma / ctDNA testing for ALK rearrangement can and cannot determine, and where the evidence stands.